FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2397211700> ?p ?o ?g. }

• W2397211700 abstract "Background: Recent discoveries of recurrent and targetable gene fusions in breast cancer suggest the need to characterize the functional significance of such genomic aberrations within larger cohorts. We quantified fusion transcript expression in patient samples using RNASeq to identify recurrent gene fusion events in breast cancer as well as study the fusions post-brief exposure to mono-therapy. Methods: We sequenced transcriptomes of core biopsy RNA from 130 breast tumors obtained from brief-exposure preoperative clinical trials BrUOG 211A/211B. HER2- patients were treated with brief exposure to bevacizumab (B) or nab-paclitaxel (nP) followed by treatment with B/nP/carboplatin while HER2+ patients received brief exposure to trastuzumab (T) or nP followed by T/nP/carboplatin. Paired-end sequencing on 75 baseline biopsies and 55 post-exposure biopsies using amplified total RNA yielded 55 million reads on average perlsample. Fusion transcript abundance was evaluated using 2 pipelines, TopHat-Fusion and deFuse, due to their complementary strategies in fusion detection. We eliminated gene-pseuodogene fusion pairs as likely false positives arising due to alignment artifacts. Fusions that met 1 or more of the following 3 criteria were considered high confidence: i) Called by both deFuse and TopHat. ii) Called by deFuse with probability >95% iii) Called by TopHat with > 15 reads supporting the fusion. Results: We identified high confidence gene fusions, detected by both TopHat and deFuse, in 73 of the 75 baseline biopsies with 16 fusions on average per sample. We looked for modulation of gene fusions upon brief exposure to therapy in 55 patients that had post exposure biopsy data and found that out of the 545 high confidence fusions detected across these patients, 62 (11.37%) of the fusions were found to be still present after the therapy exposure. For the recurrent fusion analyses, we considered the 75 baseline samples. We found a total of 1158 unique candidate fusions. Out of these, 116 (10%) were recurrent in more than 1 patient. After further filtering, we were able to narrow down to 9 (0.77%) fusions that were reliable since they were predicted by both the algorithms in different patients. 2 of these 9 fusions involved GAS5 as a partner gene. GAS5 have been studied to have a role in apoptosis and its down-regulation has been associated with cell proliferation, which makes it a very interesting fusion candidate. Conclusions: We find that gene fusions in breast cancer are highly heterogeneous but are enriched with cancer-related pathway genes. This is the first study to report 2 novel gene-lincRNA fusion transcripts: MDN1-GAS5 and GABRB3-GAS5. Both these fusions are called in the baseline & post-therapy for atleast 1 patient (different patients each). GAS5 has been found as participating in a fusion in B-cell lymphoma. We are currently in the process of validating the fusion calls using qRT-PCR. The heterogeneity of detected fusions suggests that multiple mechanisms could underlie the selective advantage of tumor cells expressing fusion transcripts. The brief-exposure preoperative paradigm provides a unique opportunity to evaluate modulation of fusion transcripts that can shed light on their functional importance. Citation Format: Agrawal V, Varadan V, Banerjee N, Miskimen K, Vadodkar A, Abu-Khalaf M, Sikov W, Harris L, Dimitrova N. Novel recurrent lncRNA fusions detected in breast cancer using RNA-Seq technology in a neoadjuvant setting. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-03-08." @default.
• W2397211700 created "2016-06-24" @default.
• W2397211700 creator A5000472860 @default.
• W2397211700 creator A5002120924 @default.
• W2397211700 creator A5005628876 @default.
• W2397211700 creator A5007357271 @default.
• W2397211700 creator A5007473380 @default.
• W2397211700 creator A5020746192 @default.
• W2397211700 creator A5020766671 @default.
• W2397211700 creator A5066507591 @default.
• W2397211700 creator A5085649942 @default.
• W2397211700 date "2016-02-15" @default.
• W2397211700 modified "2023-09-27" @default.
• W2397211700 title "Abstract P6-03-08: Novel recurrent lncRNA fusions detected in breast cancer using RNA-Seq technology in a neoadjuvant setting" @default.
• W2397211700 doi "https://doi.org/10.1158/1538-7445.sabcs15-p6-03-08" @default.
• W2397211700 hasPublicationYear "2016" @default.
• W2397211700 type Work @default.
• W2397211700 sameAs 2397211700 @default.
• W2397211700 citedByCount "0" @default.
• W2397211700 crossrefType "proceedings-article" @default.
• W2397211700 hasAuthorship W2397211700A5000472860 @default.
• W2397211700 hasAuthorship W2397211700A5002120924 @default.
• W2397211700 hasAuthorship W2397211700A5005628876 @default.
• W2397211700 hasAuthorship W2397211700A5007357271 @default.
• W2397211700 hasAuthorship W2397211700A5007473380 @default.
• W2397211700 hasAuthorship W2397211700A5020746192 @default.
• W2397211700 hasAuthorship W2397211700A5020766671 @default.
• W2397211700 hasAuthorship W2397211700A5066507591 @default.
• W2397211700 hasAuthorship W2397211700A5085649942 @default.
• W2397211700 hasConcept C104317684 @default.
• W2397211700 hasConcept C111829193 @default.
• W2397211700 hasConcept C121608353 @default.
• W2397211700 hasConcept C126322002 @default.
• W2397211700 hasConcept C143998085 @default.
• W2397211700 hasConcept C150194340 @default.
• W2397211700 hasConcept C162317418 @default.
• W2397211700 hasConcept C2778274637 @default.
• W2397211700 hasConcept C502942594 @default.
• W2397211700 hasConcept C530470458 @default.
• W2397211700 hasConcept C54355233 @default.
• W2397211700 hasConcept C71924100 @default.
• W2397211700 hasConcept C86803240 @default.
• W2397211700 hasConceptScore W2397211700C104317684 @default.
• W2397211700 hasConceptScore W2397211700C111829193 @default.
• W2397211700 hasConceptScore W2397211700C121608353 @default.
• W2397211700 hasConceptScore W2397211700C126322002 @default.
• W2397211700 hasConceptScore W2397211700C143998085 @default.
• W2397211700 hasConceptScore W2397211700C150194340 @default.
• W2397211700 hasConceptScore W2397211700C162317418 @default.
• W2397211700 hasConceptScore W2397211700C2778274637 @default.
• W2397211700 hasConceptScore W2397211700C502942594 @default.
• W2397211700 hasConceptScore W2397211700C530470458 @default.
• W2397211700 hasConceptScore W2397211700C54355233 @default.
• W2397211700 hasConceptScore W2397211700C71924100 @default.
• W2397211700 hasConceptScore W2397211700C86803240 @default.
• W2397211700 hasLocation W23972117001 @default.
• W2397211700 hasOpenAccess W2397211700 @default.
• W2397211700 hasPrimaryLocation W23972117001 @default.
• W2397211700 hasRelatedWork W2058576539 @default.
• W2397211700 hasRelatedWork W2325125940 @default.
• W2397211700 hasRelatedWork W2331056799 @default.
• W2397211700 hasRelatedWork W2341017747 @default.
• W2397211700 hasRelatedWork W2401771656 @default.
• W2397211700 hasRelatedWork W2476843004 @default.
• W2397211700 hasRelatedWork W2660498078 @default.
• W2397211700 hasRelatedWork W2736850310 @default.
• W2397211700 hasRelatedWork W2744611525 @default.
• W2397211700 hasRelatedWork W2885165836 @default.
• W2397211700 hasRelatedWork W2920903256 @default.
• W2397211700 hasRelatedWork W2940337306 @default.
• W2397211700 hasRelatedWork W2948264481 @default.
• W2397211700 hasRelatedWork W2955329330 @default.
• W2397211700 hasRelatedWork W2955668162 @default.
• W2397211700 hasRelatedWork W2965810912 @default.
• W2397211700 hasRelatedWork W2971625494 @default.
• W2397211700 hasRelatedWork W3106826384 @default.
• W2397211700 hasRelatedWork W3120836426 @default.
• W2397211700 hasRelatedWork W3181149858 @default.
• W2397211700 isParatext "false" @default.
• W2397211700 isRetracted "false" @default.
• W2397211700 magId "2397211700" @default.
• W2397211700 workType "article" @default.